Royal Philips, the parent company of Philips Healthcare, said it will integrate Dana-Farber Cancer Institute's clinical decision-support tool for cancer care into Philips' oncology informatics suite.
Implementing Dana-Farber's Clinical Pathways software will enable Philips' IntelliSpace Oncology platform to provide clinicians with appropriate treatment options for cancer patients based on information from different diagnostic modalities in various fields, including radiology, pathology, and genomics.
For example, clinicians can examine the information through electronic health record (EHR) platforms to determine the most appropriate targeted therapy for patients with advanced chronic myelogenous leukemia, among dozens of possibilities.
Philips will present its full oncology informatics suite, including this collaboration with Dana-Farber, at the upcoming 2018 American Society of Clinical Oncology (ASCO) annual meeting in Chicago.
